Cambium Bio (ASX:CMB) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Short-Term Capital Lease Obligation?

Cambium Bio's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cambium Bio's annual Short-Term Capital Lease Obligation increased from Jun. 2021 (A$0.01 Mil) to Jun. 2022 (A$0.01 Mil) but then declined from Jun. 2022 (A$0.01 Mil) to Jun. 2023 (A$0.00 Mil).

Cambium Bio Short-Term Capital Lease Obligation Historical Data

The historical data trend for Cambium Bio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Short-Term Capital Lease Obligation Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.01

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.01	-	-	-

Cambium Bio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Cambium Bio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines